Two reports showed no PRL-3 increase in lung cancer tissues compared with normal ones [15, 28], whereas another showed that PRL-3 is overexpressed in NSCLC and correlated with clinical stage [29]. This evidence concerns the gene PTP4A3 and non-small cell lung carcinoma.